Date: 2015-05-20
Type of information: Nomination
Compound:
Company: Adaptimmune (UK)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On May 20, 2015, Adaptimmune, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, announced that it has augmented its senior management team with the additions of Lini Pandite, M.D. as Senior Vice
President, Clinical Development, and Anne-Marie Martin, Ph.D. as Vice President, Head of Biomarker Research and Development.
Dr. Pandite will be responsible for global clinical development activities across Adaptimmune TCR programs. Dr. Martin will be accountable for clinical biomarker testing and companion diagnostic development activities. Drs. Pandite and Martin will report to Dr. Rafael Amado, Adaptimmune’s Chief Medical Officer.
Dr. Pandite brings over 20 years of academic, medical and pharmaceutical experience to Adaptimmune. She spent 14 years with GSK culminating in her tenure as Head Unit Physician, Oncology R&D, Vice President. While there, she was instrumental in leading the development of several compounds, including Votrient® (pazopanib), from the first study in humans through marketing
authorization and commercialization of its approved indications. She brings strong experience in oncology drug development spanning early to late phase, including clinical trial design, regulatory interactions, and clinical risk management. Dr. Pandite has practiced medicine in both the U.K. and U.S. and is board certified in hematology and oncology. Prior to joining GSK she was an attending physician at Dana-Farber Cancer Institute in Boston, and at Sylvester Comprehensive Cancer Center/Jackson Memorial Hospital in Miami and held academic appointments at Harvard University, and the University of Miami. She received her medical degree from The University of Liverpool, England.
Dr. Martin brings nearly 15 years of clinical development and biomarker experience with Pennsylvania Hospital/UPHS and GSK Oncology to Adaptimmune. She began her pharmaceutical career at GSK in 2005, and then held positions of increasing seniority with GSK Oncology, culminating in her tenure as Head of Precision Medicine and Diagnostics, GSK Oncology R&D and Head of GSK Oncology’s Molecular Medicine Unit. During her tenure, she had responsibility for clinical translational research and companion diagnostic (cDx) development for late clinical phase development. She led a global team responsible for the precision medicine strategy in Oncology to deliver all translational research into pipeline opportunities, accounting for over 10 clinical assets and an additional five assets in first-inhuman testing, and led the development of the cDx that supported the approvals of Tafinlar®
(dabrafenib) and Mekinist™ (trametinib). During her tenure, Dr. Martin contributed to three NDAs and five sNDAs. Dr. Martin has a Ph.D. in Immunogenetics from MCP-Hahnemann University, Philadelphia, PA, and was a postdoctoral Fellow and adjunct assistant professor at the University of Pennsylvania.
Financial terms:
Latest news:
